Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pegylated Interferon alpha 2b · 1 trial · 1 indication
Difference in copies of HIV DNA per CD4+ T cell between baseline and week 24, assessed by Alu-HIVgag polymerase chain reaction
| Arm | Type | Description |
|---|---|---|
| Interferon alpha | EXPERIMENTAL | pegylated Interferon alpha 2b (Pegintron) 1 µg/kg per week, 20 weeks |
| Name | Type | Description |
|---|---|---|
| Pegylated Interferon alpha 2b | DRUG | 1µg/kg/week |
Inclusion Criteria: * 18-65 years of age * Body weight between 125 and 299 lbs * Confirmed diagnosis of HIV-1 infection by western blot or by a documented HIV-1 viral load * Currently receiving ART and on ART for \> 1 year * VL \< 50 copies/ml for ≥ 1 year, with at least 2 measurements in the previ...
Top 20 of 28 competitors
Pegylated Interferon alpha 2b is used for chronic Hepatitis B and HIV-1 Infection. It is an investigational drug being developed by Merck & Company, Inc. (MRK) and is currently in Phase 2 clinical development for these infectious disease indications.
Pegylated Interferon alpha 2b is a pegylated form of interferon alpha 2b, which works by modulating the immune system to fight viral infections. It is being studied for its effects on chronic Hepatitis B and HIV-1 Infection, though its specific molecular target is not detailed.
Pegylated Interferon alpha 2b is being developed by Merck & Company, Inc., which trades under the ticker MRK. The company is conducting clinical trials to evaluate the drug for chronic Hepatitis B and HIV-1 Infection.
Pegylated Interferon alpha 2b is in Phase 2 clinical development. It is an investigational drug, not yet approved by the FDA, and is being studied for chronic Hepatitis B and HIV-1 Infection.
Pegylated Interferon alpha 2b has been studied in two completed trials. NCT00536263 was a Phase 3 trial in chronic Hepatitis B with 671 participants, and NCT01935089 was a Phase 2 pilot trial in HIV-1 Infection with 20 participants.
Yes, Pegylated Interferon alpha 2b is also known as PegIntron. The clinical trial NCT00536263, titled 'PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients,' used this name to refer to the drug.